Mercer Global Advisors
ORMP icon

Mercer Global Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

Mercer Global Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.3M Buy
3,810,540
+1,900,000
+99% +$7.56M 0.02% 377
2026
Q1 		$6.5M Buy
+1,910,540
New +$6.48M 0.01% 657

Other funds holding ORMP

AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Mercer Global Advisors's ORMP Position: Q2 2026 in Review

Mercer Global Advisors increased its Oramed Pharmaceuticals (ORMP) stake by 99% in Q2 2026, buying an estimated $7.56M and bringing the position to 3,810,540 shares worth $18.3M. The position accounts for 0.02% of the portfolio, ranked #377.

Mercer Global Advisors first reported a position in ORMP in Q1 2026 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Mercer Global Advisors held 3,810,540 shares of Oramed Pharmaceuticals worth $18.3M as of Q2 2026.
  • Mercer Global Advisors bought 1,900,000 Oramed Pharmaceuticals shares in Q2 2026, an estimated $7.56M.
  • Oramed Pharmaceuticals made up 0.02% of Mercer Global Advisors's portfolio in Q2 2026, its #377 holding.
  • Mercer Global Advisors first reported a position in Oramed Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.